Ισραήλ - Εβραϊκά - Ministry of Health

trima israel pharmaceutical products maabarot ltd - ethinylestradiol; norelgestromin - מדבקות - norelgestromin 6 mg; ethinylestradiol 0.6 mg - norelgestromin and estrogen - norelgestromin and estrogen - female contraception. evra is intended for women of fertile age.

Ισραήλ - Εβραϊκά - Ministry of Health

padagis israel pharmaceuticals ltd, israel - testosterone - ג'ל - testosterone 50 mg/dose - testosterone and estrogen - testosterone and estrogen - testosterone replacement therapy for males hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Ισραήλ - Εβραϊκά - Ministry of Health

bayer israel ltd - dienogest - טבליה - dienogest 2 mg - dienogest and estrogen - dienogest and estrogen - treatment of endometriosis.

Ισραήλ - Εβραϊκά - Ministry of Health

bayer israel ltd - estradiol valerate; estradiol valerate; norgestrel - טבליה - estradiol valerate 2 mg; norgestrel 0.5 mg; estradiol valerate 2 mg - norgestrel and estrogen - norgestrel and estrogen - two phase preparation for climacteric and cycle disturbances.

Ισραήλ - Εβραϊκά - Ministry of Health

bayer israel ltd - cyproterone acetate; ethinylestradiol - טבליה - ethinylestradiol 35 mcg; cyproterone acetate 2 mg - cyproterone and estrogen - cyproterone and estrogen - treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. for the treatment of acne, diane-35 should only be used after topical therapy or systemic antibiotic treatments have failed.

Ισραήλ - Εβραϊκά - Ministry of Health

bayer israel ltd - cyproterone acetate; ethinylestradiol - טבליה - ethinylestradiol 35 mcg; cyproterone acetate 2 mg - cyproterone and estrogen - cyproterone and estrogen - treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. for the treatment of acne, diane-35 should only be used after topical therapy or systemic antibiotic treatments have failed.

Ισραήλ - Εβραϊκά - Ministry of Health

teva israel ltd - anastrozole - טבליה - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Ισραήλ - Εβραϊκά - Ministry of Health

teva israel ltd - anastrozole - טבליה - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Ισραήλ - Εβραϊκά - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate - טבליות מצופות פילם - estradiol as hemihydrate 2 mg - estradiol - estradiol - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy.

Ισραήλ - Εβραϊκά - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg - estradiol - estradiol - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy.